Convalescent plasma for hospitalized COVID-19 patients over 40
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether donated “recovered patient” plasma (antibodies from people who had COVID-19) can improve outcomes for people hospitalized with COVID-19. It focuses on patients early in their illness who need a small amount of oxygen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 40 or older and were admitted to the University of Illinois Hospital for COVID-19
- Your COVID-19 swab test was positive within the last 72 hours
- You have COVID symptoms like fever, cough, trouble breathing, or fast breathing
- You need extra oxygen through a nasal tube at 1–5 liters per minute to keep oxygen levels above 92%
- You can provide consent and agree to store samples for future testing
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This study collects immune cells from people who recovered from COVID-19 and may use them to boost protection against SARS-CoV-2. It’s for hospitalized patients who already show a certain level of COVID-19 fighting immune response.
This study tests a treatment made from placental cells that may help reduce COVID-19 symptoms. It is for adults with mild to moderate symptoms who are overweight or obese.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests whether immune-supporting treatment made from exosomes can help people with critically severe COVID-19 and lung damage. If you qualify, you may receive this therapy as part of the study to see if it improves outcomes.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.